Check 35,000+ stocks against 26 valuation models and 37 quality factors

AbbVie Inc (ABBV) fair value: what the stock is really worth

We calculate from audited financials what AbbVie Inc is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

Fair value above price? No
Good quality? Yes
Add to watchlist

Healthcare · US · ISIN US00287Y1091

Broad data Sep 17, 2026

AbbVie Inc

ABBV · US

NeutralQuality growthThe stock looks roughly fairly valued with average quality.

·Fair value $259.66 · Fairly valued (−2%)

✓Quality 74/100

!Mixed Growth (revenue 5y +6.0 %/yr)

!Thin margins · 5.8% net margin (TTM)

✓Negative equity (buybacks among others) · generates free cash flow

·2.55% dividend yield

✓Ranks above peers (9/14)

✓Wide moat 78/100

!Insider activity 45/100

26 models, one by oneBear $147.66 to bull $358.90 Growth analysisrevenue history, year by year Quality 74/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch AbbVie Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 17, 2026.

How to read this chart

60‑month range $88.56 – $265.97 · fair‑value band $147.66 – $358.90 · the $263.96 price screens above the $259.66 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 17, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Stock analysis

AbbVie Inc (ABBV) currently trades at $263.96, while our model-based Fair Value estimate is $259.66, implying the stock looks roughly 1.7% fairly valued today.

Valuation

Bull case: the Dividend Discount group reads highest at a median of $113.50 per share, and 0 of the 23 models we run sit above the $263.96 price.

Bear case: the Growth Earnings group reads lowest at $40.81, and 23 of the 23 models stay below the price. Evidence for this calculation is high.

Scenario range: $147.66 (bear) to $358.90 (bull), the price of $263.96 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 74/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

AbbVie Inc reported revenue of $61.2B in FY2025 versus $56.2B in FY2021, a compound +2.1%/yr. Reported net income was $4.2B in FY2025, compounding −22.2%/yr from FY2021.

Key figures

Market cap $468B · P/E ratio 118.9 · P/S ratio 8.21 · EPS (TTM) $2.04 · Dividend yield 2.6% · Net margin 6.9% · Return on equity 62.3% · Return on assets (EBIT) 11.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 58 out of 100 (medium confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades near its 52-week high and 50% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −2%, ABBV screens richer than that median.

Fair Value models

Bear $147.66 Fair Value $259.66 Bull $358.90

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF $98.39 $191.36 $350.26 77

Growth DCF $99.49 $190.65 $347.76 75

EPV $69.93 $87.64 $103.38 74

All 23 models by family

DCF Models

FCF DCF $98.39 $191.36 $350.26 77

Owner Earnings $50.21 $108.40 $207.86 72

5Y Revenue Exit $58.94 $111.66 $179.89 70

5Y EBITDA Exit $114.38 $220.62 $349.42 73

5Y P/E Exit $35.24 $65.08 $96.55 69

10Y Revenue Exit $68.67 $122.34 $197.55 65

10Y EBITDA Exit $108.00 $201.86 $336.25 66

10Y P/E Exit $55.37 $88.35 $129.37 63

Earnings-Based

Graham-Dodd $16.26 $63.01 $85.44 64

Lynch FV $15.44 $22.05 $28.67 61

PEG = 1.0 $15.44 $22.05 $28.67 57

EPV $69.93 $87.64 $103.38 74

Dividend Discount

Gordon GGM $63.46 $138.55 $233.12 65

DDM Multi-Stage $63.46 $113.50 $144.40 66

Multiples

P/E Multiple $39.47 $52.62 $65.78 63

P/S Multiple $30.50 $40.66 $50.83 58

EV/EBIT $114.59 $162.91 $211.24 65

EV/EBITDA $137.37 $193.29 $249.22 67

EV/Revenue $42.29 $73.45 $104.60 52

Growth DCF

Growth DCF $99.49 $190.65 $347.76 75

Rev-Margin DCF $58.94 $111.80 $176.66 71

Economic Profit

ROIC Compounder $79.35 $111.24 $149.42 71

Growth Earnings

Growth-Adj P/E $28.57 $40.81 $53.05 67

Open the full fair value analysis →

Notify me when ABBV reaches fair value

Put ABBV on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 74/100

Of which business quality 68 · Market factors (momentum, volatility) 78

Profitability 39

Margins and returns on capital today

Quality Growth 58

Are margins and returns improving?

Cashflow 99

Earnings quality: real cash, not paper profit

Fin. Strength 47

Balance sheet, leverage, solvency risk

Investment 100

Disciplined investing over empire-building

Low Volatility 88

Calm price path (market factor)

Momentum 71

Price trend over the last 3–12 months (market factor)

52W Momentum 80

Distance to the 52-week high (market factor)

Net Issuance 82

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 76/100

Revenue is growing, but margins or cash flow do not fully confirm the trend.

Revenue growth 1 year

+8.6%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+1.8%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+6.0%

Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+9.5%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.

−6.5%

Earnings growth per share plus dividend.

Earnings per share, growth per year−9.1%

Dividend (yield on the price)2.6%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−15% vs −3%, slowing

Profit margin 2018 to 2024 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.20% → 16%

Growth Forecast

A lot of optimism in the price

The price assumes more growth than the company has delivered so far and more than analysts expect.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+10.7%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.

+7.7%

Yearly sales growth analysts expect, extended to five years.

Forecast 2026 (sales)+10.0%

Forecast 2027 (sales)+8.3%

Projected 2028 (sales)+7.5%

Projected 2029 (sales)+6.7%

Projected 2030 (sales)+5.9%

Watch ABBV, get fair value alerts →

Compare AbbVie Inc with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 73 stocks

Beats the industry median on 7/13 measures

A mixed picture versus its industry peers.

Valuation

Quality Score 74 · Top 25%

Fair Value upside −74% · Bottom 25%

Profitability

Return on equity (TTM) 62% · Top 25%

Return on assets 10% · Top 25%

Net margin (TTM) 6% · Below median

Operating margin (TTM) 32% · Top 25%

Growth and dividend

Revenue growth 12% · Above median

Dividend yield (TTM) 2.6% · Above median

Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper

P/E (TTM) 118.9× · Priciest 25%

P/S (TTM) 7.16× · Priciest 25%

P/FCF 25.2× · Pricier than median

EV/EBITDA 16.8× · Pricier than median

PEG 0.40× · Cheapest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)31 · sector 9

FUTURE (revenue growth)62 · sector 27

PAST (return on equity)100 · sector 49

HEALTH (low debt)100 · sector 94

DIVIDEND (yield)51 · sector 41

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Eli Lilly and Company LLY	$1,136	$778.94	−31%
Johnson & Johnson, JNJ	$267.20	$169.04	−37%
Roche Holding RO	CHF 369.80	CHF 306.54	−17%
Merck & Co MRK	€124.22	€101.89	−18%
Novartis AG NVS	$140.37	$138.70	−1%
Novo Nordisk A/S NOVOB	kr 272.60	kr 409.46	+50%
Amgen Inc AMGN	$375.65	$413.22	+10%
Gilead Sciences, Inc GILD	$146.30	$198.51	+36%
Pfizer Inc PFE	$27.55	$20.39	−26%
Bristol-Myers Squibb Company BMY	$63.73	$75.98	+19%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

AbbVie Inc · Fair Value
$259.66 −2%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/ABBV" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">AbbVie Inc · Fair Value</span><br><b style="font-size:20px">$259.66</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−2%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "AbbVie Inc Fair Value". https://www.fairvalue-calculator.com/stock/ABBV

Frequently asked questions

Is AbbVie Inc (ABBV) overvalued or undervalued?

As of Sep 17, 2026, our model estimates a fair value of $259.66 versus a price of $263.96, about −2% upside (fairly valued).

What is the fair value of ABBV?

Our model-based fair value for AbbVie Inc is $259.66 (as of Sep 17, 2026), built from audited fundamentals. The current price: $263.96.

What is the quality score of ABBV?

AbbVie Inc has a Quality Score of 74/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for AbbVie Inc (ABBV)?

Our model-based price target is the fair value of $259.66 (as of Sep 17, 2026) from 23 valuation models. Cautious scenario $147.66, optimistic scenario $358.90. It is a calculation from audited fundamentals, not an analyst target.

What is the AbbVie Inc stock forecast for 2026?

Our models put fair value at $259.66, about −2% upside versus a price of $263.96 (fairly valued). Cautious scenario $147.66, optimistic scenario $358.90. The calculation is refreshed regularly with new filings.

What is the revenue of AbbVie Inc (ABBV)?

AbbVie Inc reported trailing-twelve-month revenue of about $62.8B (latest available figure, as of Sep 17, 2026).

Does AbbVie Inc pay a dividend?

AbbVie Inc currently shows a dividend yield of about 2.55% relative to its recent price (as of Sep 17, 2026).

What growth is priced into AbbVie Inc (ABBV)?

For today's price to be fair in a discounted-cash-flow model, AbbVie Inc would have to grow free cash flow by +10.7 % per year for five years (discount rate 7.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.0 % per year. As of Sep 17, 2026.

What discount rate (WACC) does the fair value of ABBV use?

Our models discount AbbVie Inc at 7.6 %: a base by market capitalisation (mega), damped by beta 0.31, country premium for USA. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For AbbVie Inc that is +10.7 % per year a year over ten years, using the same discount rate (7.6 %) and the same formula as our fair value.

How much growth has AbbVie Inc (ABBV) delivered so far?

Over the past 5 years revenue at AbbVie Inc grew +6.0 % a year. The price currently implies +10.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of AbbVie Inc (ABBV) growing?

The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into AbbVie Inc (+10.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of AbbVie Inc (ABBV)?

The free-cash-flow yield on the price is 3.80 %: that much free cash flow AbbVie Inc produces per unit of market value. When it exceeds the discount rate of our models (7.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of AbbVie Inc (ABBV)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For AbbVie Inc it is $259.66 per share (as of Sep 17, 2026), against a price of $263.96. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).

Is AbbVie Inc stock overvalued or undervalued in 2026?

As of Sep 17, 2026, ABBV trades above its calculated fair value: price $263.96, fair value $259.66, a gap of about −2% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of ABBV?

No. The price is what the market pays today ($263.96); the fair value is what the company's own numbers justify ($259.66). For AbbVie Inc the two are $4.30 per share apart. That gap is exactly why we show both numbers side by side.

How much is AbbVie Inc worth?

The market values AbbVie Inc at about $468B (market capitalisation, as of Sep 17, 2026). Per share that is $263.96; our models calculate a fair value of $259.66 per share.

What do the bullish and bearish scenarios say about ABBV?

Our models span a range for AbbVie Inc: cautious scenario $147.66, base $259.66, optimistic $358.90 per share (as of Sep 17, 2026, price $263.96). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of ABBV?

AbbVie Inc trades at a price-to-earnings ratio of 118.9 (as of Sep 17, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $259.66 is built from several models across several years. Other multiples: PEG 0.4, P/S 7.2, EV/EBITDA 16.8.

What is the PEG ratio of ABBV?

The PEG ratio of AbbVie Inc is 0.40 (P/E divided by earnings growth, as of Sep 17, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.

How solid is the balance sheet of AbbVie Inc (ABBV)?

Balance-sheet figures for AbbVie Inc (as of Sep 17, 2026): return on equity 62.3%. They feed the Quality Score of 74/100, which measures business quality independently of the share price.

How far is ABBV from its 52-week high?

AbbVie Inc trades at $263.96, about 10% below its 52-week high of $239.13 and 50% above the low of $176.00 (as of Sep 17, 2026). Distance from the high says nothing about value: that is what the fair value of $259.66 is for.

Which stocks are comparable to AbbVie Inc?

From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, Roche Holding, Merck & Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is AbbVie Inc stock attractive at the current price?

The data as of Sep 17, 2026: price $263.96, calculated fair value $259.66 (−2%), Quality Score 74/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of ABBV calculated?

We run AbbVie Inc through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $259.66, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 16.1 % above its aggregate fair value. AbbVie Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of AbbVie Inc (ABBV)?

The closing price on Sep 18, 2026 was $263.96. Our model-based fair value is $259.66, about −2% upside (fairly valued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with AbbVie Inc right now?

The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range ($147.66 to $358.90) leaves room in how you read the outcome.

Where does the earnings growth of AbbVie Inc (ABBV) come from?

Earnings per share at AbbVie Inc grew −0.5 % a year from 2014 to 2025. Broken into its drivers: revenue per share +9.7 %, EBIT margin −2.1 %, tax rate +0.7 %, residual (interest, one-offs) −8.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of AbbVie Inc

How large is the market capitalisation of AbbVie Inc (ABBV)?

The market capitalisation of AbbVie Inc is $468B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of AbbVie Inc (ABBV)?

The price-to-sales ratio of AbbVie Inc is 8.21 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of AbbVie Inc (ABBV)?

Earnings per share at AbbVie Inc are $2.04 (price ÷ EPS = P/E 118.9). Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of AbbVie Inc (ABBV)?

The dividend yield of AbbVie Inc is 2.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of AbbVie Inc (ABBV)?

The net margin of AbbVie Inc is 6.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of AbbVie Inc (ABBV)?

The return on equity (ROE) of AbbVie Inc is 62.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of AbbVie Inc (ABBV)?

On an EBIT basis the return on assets of AbbVie Inc is 11.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of AbbVie Inc (ABBV)?

The operating margin of AbbVie Inc is 32.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at AbbVie Inc (ABBV)?

Revenue at AbbVie Inc is growing +12.4% versus a year earlier (3y avg +1.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at AbbVie Inc (ABBV)?

Earnings per share at AbbVie Inc are growing −46.2% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net debt does AbbVie Inc (ABBV) carry?

The net debt of AbbVie Inc is $63.8B (fiscal year 2025, ≈ 3.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch AbbVie Inc in the live analysis

One click puts AbbVie Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.